Certolizumab pegol: A new biologic targeting rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 855-866

  Patel, Aarat M ^a   Moreland, Larry W ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

anti TNF therapy; biologics; certolizumab pegol; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CHEMOKINE; CHIMERIC ANTIBODY; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYBRID PROTEIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR ALPHA; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

BACKACHE; BODY WEIGHT; BRONCHITIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HEART FAILURE; HUMAN; HYPERTENSION; INFECTION; LOW DRUG DOSE; LYMPHOMA; NEOPLASM; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHARYNGITIS; PNEUMONIA; PRACTICE GUIDELINE; PRODUCTIVITY; RECOMMENDED DRUG DOSE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TUBERCULOSIS; URINARY TRACT INFECTION; URTICARIA; VIRUS REACTIVATION; WORK;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; METHOTREXATE; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049441840     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.69     Document Type: Review

References (63)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358(9285), 903-911 (2001).
2. Spector TD. Rheumatoid arthritis. Rheum. Dis. Clin. North Am. 16(3), 513-537 (1990).
3. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4(Suppl. 3), S265-S272 (2002).
4. Fuchs HA, Kaye JJ, Callahan LF et al. Evidence of signifcant radiographic damage in rheumatoid arthritis within the frst 2 years of disease. J. Rheumatol. 16(5), 585-591 (1989).
5. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008).
6. Emery P, Van Vollenhoven R, Ostergaard M et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68(4), 456-459 (2009).
7. Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 52(11), 3360-3370 (2005).
8. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. 333(3), 142-146 (1995).
9. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334(20), 1287-1291 (1996).
10. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infiximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
11. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
12. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375-382 (2008).
13. Boers M. Cost-effectiveness of biologics as frst-line treatment of rheumatoid arthritis: case closed? Ann. Intern. Med. 151(9), 668-669 (2009).
14. Maini R, St Clair EW, Breedveld F et al. Infiximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999).
15. van Vollenhoven RF, Ernestam S, Harju A et al. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more effcacious. Arthritis Res. Ther. 5(6), R347-R351 (2003).
16. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003).
17. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46(6), 1443-1450 (2002).
18. Lipsky PE, van der Heijde DM, St Clair EW et al. Infiximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
19. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50(5), 1400-1411 (2004).
20. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary effcacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006).
21. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
22. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008).
23. van Vollenhoven R, Harju A, Brannemark S et al. Treatment with infiximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis. 62(12), 1195-1198 (2003).
24. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet 374(9685), 210-221 (2009).
25. Emery P, Kosinski M, Li T et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate signifcantly improved health-related quality of life. J. Rheumatol. 33(4), 681-689 (2006).
26. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006).
27. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987-997 (2008).
28. Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48(4), 927-934 (2003).
29. Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum. 58(5), 1299-1309 (2008).
30. Genovese MC, Kaine JL, Lowenstein MB et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(9), 2652-2661 (2008).
31. Senolt L, Vencovsky J, Pavelka K et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev. 9(2), 102-107 (2009).
32. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1β for the potential treatment of infammatory disorders. Curr. Opin. Mol. Ther. 11(1), 81-89 (2009).
33. Baslund B, Tvede N, Danneskiold-Samsoe B et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study Arthritis Rheum. 52(9), 2686-2692 (2005).
34. Plater-Zyberk C, Joosten LA, Helsen MM et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model. Ann. Rheum. Dis. 68(5), 721-728 (2009).
35. Leonardi CL, Kimball AB, Papp KA et al. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625), 1665-1674 (2008).
36. Yago T, Nanke Y, Kawamoto M et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9(5), R96 (2007).
37. Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeated-dose study Arthritis Rheum. 58(1), 61-72 (2008).
38. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther. 10(3), 294-309 (2008).
39. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and effcacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
40. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11), 3309-3318 (2008).
41. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Infamm. Bowel Dis. 13(11), 1323-1332 (2007).
42. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is signifcantly more effective than placebo plus methotrexate in active rheumatoid arthritis: fndings of a ffty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319-3329 (2008).
43. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Effcacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68(6), 805-811 (2009).
44. Smolen J, Landewe RB, Mease P et al. Effcacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study A randomised controlled trial. Ann. Rheum. Dis. 68(6), 797-804 (2009).
45. Keystone E, Fleischmann R, Smolen J et al. The effcacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum. 60(Suppl. 9) (2009) (Abstract 1666).
46. Strand V, Fleischmann R, Kvien TK et al. Certolizumab pegol added to methotrexate provides lasting improvements in patient-reported outcomes over 2 years. Arthritis Rheum. 60(Suppl. 9) (2009) (Abstract 1698).
47. Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res. Ther. 11(6), R170 (2009).
48. Kavanaugh A, Smolen JS, Emery P et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res. 61(11), 1592-1600 (2009).
49. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum. 31(3), 315-324 (1988).
50. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology Preliminary defnition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995).
51. van der Heijde DM, van Riel PL, Nuver-Zwart IH et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1(8646), 1036-1038 (1989).
52. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J. Rheumatol. 30(1), 167-178 (2003).
53. Strand V, Scott DL, Emery P et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of lefunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J. Rheumatol. 32(4), 590-601 (2005).
54. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31(3), 247-263 (1993).
55. Tack BB. Self-reported fatigue in rheumatoid arthritis. A pilot study. Arthritis Care Res. 3(3), 154-157 (1990).
56. Farrar JT, Young JP Jr, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2), 149-158 (2001).
57. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specifc Work Productivity Survey (WPS-RA). Arthritis Res. Ther. 11(3), R73 (2009).
58. Bendele A, Seely J, Richey C et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42(2), 152-157 (1998).
59. Webster R, Didier E, Harris P et al. PEGylated proteins: evaluation of their safety in the absence of defnitive metabolism studies. Drug Metab. Dispos. 35(1), 9-16 (2007).
60. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
61. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130(6), 478-486 (1999).
62. van de Putte LB, Atkins C, Malaise M et al. Effcacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63(5), 508-516 (2004).
63. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000).